Tracey A. Day

Tuberculosis following PD-1 blockade for cancer immunotherapy

Shunsuke Sakai, Ragini R. Kudchadkar, Steven P. Fling et al. · Science Translational Medicine · 2019 · 198 citations · Full text

Life Sciences, Immunology, Oncology +14

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

Rhea N. Coler, Tracey A. Day, Ruth D. Ellis et al. · npj Vaccines · 2018 · 164 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial

Adam Penn‐Nicholson, Michèle Tameris, Erica Smit et al. · The Lancet Respiratory Medicine · 2018 · 149 citations

Veterinary Medicine, Immunology, Infectious Diseases +15

Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial

Tracey A. Day, Adam Penn‐Nicholson, Angelique Kany Kany Luabeya et al. · The Lancet Respiratory Medicine · 2020 · 103 citations

Veterinary Medicine, Immunology, Infectious Diseases +10

Mycobacterium tuberculosis Strains Lacking Surface Lipid Phthiocerol Dimycocerosate Are Susceptible to Killing by an Early Innate Host Response

Tracey A. Day, John E. Mittler, Molly R Nixon et al. · Infection and Immunity · 2014 · 68 citations · Full text

Life Sciences, Immunology, Microbiology +17